Evaluation of ceramic marker for the treatment of ocular melanoma with proton therapy
Authors:
- 14 March 2017
- journal article
- research article
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 3 (2) , 027003
Abstract
BioMarc SecureTM, a fiducial marker with ceramic core (zirconium oxide) and carbon coating, was evaluated for use in the localization and alignment of ocular melanoma targets using proton pencil beam scanning (PBS). Measurements and Monte Carlo (MC) simulations were performed to estimate the dose attenuation behind the marker. Imaging tests were performed to evaluate the visibility of marker for x-ray based alignment. An anthropomorphic phantom with implanted fiducial marker was scanned to obtain two-dimensional kilo-voltage (kV) x-ray and three-dimensional computed tomographic (CT) images. For dose shadow measurements, an in-house phantom was constructed using solid water, Styrofoam and EBT3 gafchromic film. Dose attenuation behind the marker was measured at multiple depths and for three cardinal orientations: parallel, perpendicular, and transverse. The measurements were performed at the proton pencil beam gantry at the Seattle Cancer Care Alliance Proton Therapy center. A beam model for pencil beam gantry was created in the validated MC simulation toolkit GATE (GEANT4 Applications for Tomographic Emission). MC simulations were set up to mimic the measurement geometry and dose attenuation behind the marker was studied for a single layer PBS beam. Additional simulations were performed in water using the clinical relevant spread out Bragg peak (SOBP) beam. Qualitative analysis of the planar kV images showed excellent visibility of marker. Reconstruction artifacts in the form of light and dark streaks were present on the CT images. The film and MC simulations showed significant dose attenuation behind the marker that worsened when marker was placed close to the distal edge. Dose shadows of up to 45% and range loss of up to 1.1 mm were seen behind the marker. The transverse marker orientation in the clinical SOBP beam showed dose reduction of up to 61% and range pull-back of 2.4 mm. The dose attenuation was found to be a function of marker orientation and location within the SOBP. The analysis showed that small volumes behind the marker can see severe under-dosing. This effect should be taken into account during the planning of treatment. Comparing the results of this study to published results for tantalum marker, the BioMarc Secure marker was found to be inferior due to its greater dose attenuation and extended dose shadow on larger underlying volume. Furthermore, its bigger physical size may mean more discomfort to patient.Keywords
This publication has 31 references indexed in Scilit:
- Measurements of 2D distributions of absorbed dose in protontherapy with Gafchromic EBT3 filmsApplied Radiation and Isotopes, 2015
- Characterization of a new commercial single crystal diamond detector for photon- and proton-beam dosimetryJournal of Radiation Research, 2015
- Under-response correction for EBT3 films in the presence of proton spread out Bragg peaksPhysica Medica, 2014
- Proton beam radiotherapy of uveal melanomaSaudi Journal of Ophthalmology, 2013
- Intraoperative Localization of Tantalum Markers for Proton Beam Radiation of Choroidal Melanoma by an Opto-Electronic Navigation System: A Novel TechniqueInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Dose perturbations from implanted helical gold markers in proton therapy of prostate cancerJournal of Applied Clinical Medical Physics, 2009
- Application of flat panel digital imaging for improvement of ocular melanoma patient set-up in proton beam therapyNuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2009
- Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- Results of proton therapy of uveal melanomas treated in NiceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Résultats préliminaires de la protonthérapie du mélanome de la choroïde au centre de protonthérapie d'Orsay (CPO): Les 464 premiers casCancer/Radiothérapie, 1997